Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Connecticut: - Hartford HealthCare - Avon — Avon, Connecticut
- Hartford HealthCare - Saint Vincent's Medical Center — Bridgeport, Connecticut
- Danbury Hospital — Danbury, Connecticut
- Smilow Cancer Hospital-Derby Care Center — Derby, Connecticut
- Hartford Healthcare - Fairfield — Fairfield, Connecticut
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Connecticut: - Stamford Hospital/Bennett Cancer Center — Stamford, Connecticut
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in Connecticut: - University of Connecticut Health Center ( Site 0128) — Farmington, Connecticut
- Yale Cancer Center ( Site 0053) — New Haven, Connecticut
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in Connecticut: - Smilow Cancer Hospital at Yale New Haven — New Haven, Connecticut
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Connecticut: - Research Site — New Haven, Connecticut
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in Connecticut: - Yale-New Haven Hospital-Yale Cancer Center — New Haven, Connecticut
Phase 3 Recruiting Industry
This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, hu…
Sponsor: Hoffmann-La Roche
NCT ID: NCT05646862
Sites in Connecticut: - Eastern CT Hematology and Oncology Associates — Norwich, Connecticut
Phase 2 Recruiting Academic/Other
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in Connecticut: - Smilow Cancer Hospital Care center at Derby — Derby, Connecticut
- Smilow Cancer Hospital Care center at Fairfield — Fairfield, Connecticut
- Smilow Cancer Hospital Care center at Glastonbury — Glastonbury, Connecticut
- Smilow Cancer Hospital Care center at Greenwich — Greenwich, Connecticut
- Smilow Cancer Hospital Care center at Guilford — Guilford, Connecticut
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Connecticut: - Yale University, Yale Cancer Center — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 2 Recruiting NIH
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has sprea…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03606967
Sites in Connecticut: - Smilow Cancer Hospital Care Center at Saint Francis — Hartford, Connecticut
- Yale University — New Haven, Connecticut
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Connecticut: - Norwalk Hospital — Norwalk, Connecticut
Phase 2 Recruiting Academic/Other
This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The nam…
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04468061
Sites in Connecticut: - Stamford Hospital — Stamford, Connecticut
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of…
Sponsor: Tubulis GmbH
NCT ID: NCT06657222
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 2 Recruiting Academic/Other
The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to lea…
Sponsor: Ana C Garrido-Castro, MD
NCT ID: NCT06533826
Sites in Connecticut: - Yale University Cancer Center — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
The aim of this study is to identify the optimal dose for EP0062 as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advance…
Sponsor: Ellipses Pharma
NCT ID: NCT05573126
Sites in Connecticut: - Yale School of Medicine — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination …
Sponsor: Simcha IL-18, Inc.
NCT ID: NCT04787042
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 1 Recruiting Industry
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Sponsor: Normunity AccelCo, Inc.
NCT ID: NCT07182149
Sites in Connecticut: - Normunity Investigational Site — New Haven, Connecticut
Phase 1 Recruiting Industry
The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main que…
Sponsor: NiKang Therapeutics, Inc.
NCT ID: NCT07029399
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 1 Recruiting Industry
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with a…
Sponsor: Cogent Biosciences, Inc.
NCT ID: NCT07361562
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 1 Recruiting Industry
This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unrese…
Sponsor: Immunome, Inc.
NCT ID: NCT07578571
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 1 Recruiting Industry
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.
Sponsor: Duke Street Bio Ltd
NCT ID: NCT06458712
Sites in Connecticut: - Yale Cancer Center - Yale New Haven Hospital — New Haven, Connecticut
Phase 1 Recruiting Industry
The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expr…
Sponsor: EMD Serono Research & Development Institute, Inc.
NCT ID: NCT07360314
Sites in Connecticut: - Yale University - Yale University School of Medicine — New Haven, Connecticut
Phase 1 Recruiting Industry
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
Sponsor: Kivu Bioscience Inc.
NCT ID: NCT07229313
Sites in Connecticut: - Kivu Trial Site — New Have, Connecticut